Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain
Thursday, May 29, 2025Taiwanbased Formosa Pharmaceuticals Formosa TW announced that the company has entered into an exclusive licensing agreement with Adalvo Limited Adalvo in the European and Brazilian markets for exclusive rights
Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
Thursday, May 29, 2025Nuclera the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery System has announced a collaboration with Cytiva a global life sciences leader
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
Wednesday, May 28, 2025Ocugen Inc a pioneering biotechnology leader in gene therapies for blindness diseases today announced that the United States Food and Drug Administration US FDA has granted Rare Pediatric Disease Designation RPDD for OCUST
Drug Farm and Xiamen Amoytop Biotech Co., Ltd. Enter into Option Agreement for First-In-Class Innate Immunity Agonist, DF-006 to Treat Hepatitis B and Hepatocellular Cancer
Wednesday, May 28, 2025Drug Farm a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop innovative immunemodulating therapies today announced that it has entered into
AbelZeta Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for C-CAR168 for the Treatment of Refractory SLE, Including LN
Wednesday, May 28, 2025AbelZeta Pharma Inc a global clinicalstage biopharmaceutical company focused on discovery and development of innovative and proprietary cellbased therapeutic products today announced that the US Food and Drug Administration
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Tuesday, May 27, 2025Rein Therapeutics a biopharmaceutical company advancing a novel pipeline of firstinclass medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications announced today that the first patient has been dosed
Bio Usawa and Pacific Environmental Technologies Announce Landmark Partnership to Develop and Deploy Modular cGMP Biomanufacturing Units for Africa
Friday, May 23, 2025Bio Usawa Inc a biopharmaceutical company based in San Francisco Kigali and Nairobi committed to expanding access to lifesaving biologics in Africa and underserved regions today announced an agreement with Pacific Environmental Technologies Inc a glo...
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
Friday, May 23, 2025Cullinan Therapeutics Inc Taiho Pharmaceutical Co Ltd and Taiho Oncology Inc today announced new positive results from the pivotal Phase b cohorts of the REZILIENT trial a Phase clinical trial of zipalertinib monotherapy in patients with advanced or...
Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer
Thursday, May 22, 2025Orionis Biosciences a privately held clinicalstage life sciences company focused on the rational discovery and development of drug modalities with induced proximity mode of action today announced a second multiyear collaboration with Genentech a memb...
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor
Thursday, May 22, 2025Avenzo Therapeutics Inc a clinicalstage biotechnology company developing nextgeneration oncology therapies today announced clearance by the US Food and Drug Administration FDA of its investigational new drug application IND for AVZO formerly ARTS a p...
